The EoE-centered framework supports disease modeling, multidimensional efficacy endpoints, type 2 biomarker analysis, and cross-indication translational research<\/b><\/p>\n
BOSTON and SUZHOU, China<\/span>, June 24, 2026<\/span> \/PRNewswire\/ — HKeyBio, a preclinical contract research organization focused on autoimmune and allergic diseases, today announced the launch of HKEY-ExE\u2122 1.0<\/b>, an EoE&EgE Evaluation Framework<\/b> for eosinophilic esophagitis (EoE), eosinophilic gastroenteritis (EgE, also referred to as EGE), and related eosinophilic gastrointestinal disorders (EGIDs).<\/p>\n HKEY-ExE\u2122 1.0 is designed for drug developers working on type 2 inflammation, eosinophil recruitment, epithelial barrier dysfunction, tissue inflammation, and remodeling. The framework integrates disease modeling, in vivo efficacy evaluation, biomarker analysis, pathology assessment, mechanism-of-action studies, and cross-indication translational support.<\/p>\n EoE Development Is Advancing, While Broader EGIDs Need More Interpretable Preclinical Tools<\/b><\/p>\n EoE is a chronic, antigen-driven, immune-mediated disease of the esophagus, characterized by eosinophil infiltration, inflammation, epithelial barrier dysfunction, tissue injury, and remodeling. EgE and other non-esophageal EGIDs may involve the stomach, small intestine, colon, or multiple gastrointestinal tissue sites, creating complexity in model construction, histological evaluation, biomarker selection, and translational data interpretation.<\/p>\n For candidates targeting IL-4\/IL-13, IL-5, TSLP, Siglec-8, the CCR3\/eotaxin axis, and other eosinophilic inflammation-related pathways, early preclinical studies need to clarify in vivo activity, tissue inflammation reduction, biomarker modulation, and cross-indication potential.<\/p>\n HKeyBio Builds HKEY-ExE\u2122 1.0 Around Four Core Modules<\/b><\/p>\n 1. Disease Modeling for EoE and Related EGIDs<\/b><\/p>\n HKeyBio supports preclinical study design and animal model development based on allergen-induced modeling strategies and immuno-inflammatory disease research experience. Protocols can be adapted by candidate mechanism, molecule type, target biology, development stage, and project objectives.<\/p>\n For EoE studies, evaluation may focus on eosinophil infiltration, inflammatory cell recruitment, tissue injury, epithelial barrier changes, and fibrosis-related alterations. For EgE and other EGIDs, the framework may be extended to additional gastrointestinal tissue sites and disease-related molecular signals.<\/p>\n 2. Multidimensional Efficacy Endpoint Evaluation<\/b><\/p>\n Efficacy assessment in eosinophilic gastrointestinal diseases cannot rely on a single endpoint. HKEY-ExE\u2122 1.0 combines histology, cytology, molecular biology, pathology, and biomarker analysis.<\/p>\n Depending on study objectives, endpoints may include:<\/p>\n 3. Type 2 and Eosinophilic Inflammation Biomarker Analysis<\/b><\/p>\n HKeyBio has established biomarker detection and analysis capabilities for key inflammatory pathways, including IL-4, IL-5, IL-13, TSLP, eotaxin family chemokines, and other molecules related to eosinophil recruitment, activation, and tissue infiltration.<\/p>\n These studies can help research teams evaluate expected pathway activity, inflammatory cascade modulation, and scientific rationale for later-stage development.<\/p>\n 4. Cross-Indication Translational Research Support<\/b><\/p>\n EoE, EgE, and other allergic inflammatory diseases share overlapping features, including type 2 inflammation, eosinophil recruitment, barrier dysfunction, and tissue remodeling. HKEY-ExE\u2122 1.0 supports mechanism validation, model selection, endpoint design, and translational pathway assessment for multi-indication strategies.<\/p>\n “EoE, EgE, and related EGIDs share important immuno-inflammatory characteristics, but they differ in affected tissue sites, pathological features, and endpoint evaluation requirements,” said a representative of HKeyBio. “HKEY-ExE\u2122 1.0 is designed to provide global drug developers with more systematic, interpretable, and mechanism-oriented preclinical research support.”<\/p>\n Looking ahead, HKeyBio will continue to strengthen disease model resources and translational research capabilities for EoE, EgE, and related EGIDs.<\/p>\n About HKeyBio<\/b><\/p>\n HKeyBio is a preclinical contract research organization focused on autoimmune and allergic diseases, providing in vivo pharmacology evaluation and translational research services from drug discovery through IND-enabling preparation. The company has established rodent and non-human primate preclinical platforms covering disease modeling, efficacy evaluation, mechanism-of-action studies, biomarker analysis, pathology testing, and translational medicine research.<\/p>\n HKeyBio’s core technical team has more than 20 years of autoimmune disease drug development experience and has supported more than 500 autoimmune disease-related IND research programs.<\/p>\n For more information, please contact:<\/b> <\/p>\n The EoE-centered framework supports disease modeling, multidimensional efficacy endpoints, type 2 biomarker analysis, and cross-indication translational research<\/b><\/p>\n BOSTON and SUZHOU, China<\/span>, June 24, 2026<\/span> \/PRNewswire\/ — HKeyBio, a preclinical contract research organization focused on autoimmune and allergic diseases, today announced the launch of HKEY-ExE\u2122 1.0<\/b>, an EoE&EgE Evaluation Framework<\/b> for eosinophilic esophagitis (EoE), eosinophilic gastroenteritis (EgE, also referred to as EGE), and related eosinophilic gastrointestinal disorders (EGIDs).<\/p>\n HKEY-ExE\u2122 1.0 is designed for drug developers working on type 2 inflammation, eosinophil recruitment, epithelial barrier dysfunction, tissue inflammation, and remodeling. The framework integrates disease modeling, in vivo efficacy evaluation, biomarker analysis, pathology assessment, mechanism-of-action studies, and cross-indication translational support.<\/p>\n EoE Development Is Advancing, While Broader EGIDs Need More Interpretable Preclinical Tools<\/b><\/p>\n EoE is a chronic, antigen-driven, immune-mediated disease of the esophagus, characterized by eosinophil infiltration, inflammation, epithelial barrier dysfunction, tissue injury, and remodeling. EgE and other non-esophageal EGIDs may involve the stomach, small intestine, colon, or multiple gastrointestinal tissue sites, creating complexity in model construction, histological evaluation, biomarker selection, and translational data interpretation.<\/p>\n For candidates targeting IL-4\/IL-13, IL-5, TSLP, Siglec-8, the CCR3\/eotaxin axis, and other eosinophilic inflammation-related pathways, early preclinical studies need to clarify in vivo activity, tissue inflammation reduction, biomarker modulation, and cross-indication potential.<\/p>\n HKeyBio Builds HKEY-ExE\u2122 1.0 Around Four Core Modules<\/b><\/p>\n 1. Disease Modeling for EoE and Related EGIDs<\/b><\/p>\n HKeyBio supports preclinical study design and animal model development based on allergen-induced modeling strategies and immuno-inflammatory disease research experience. Protocols can be adapted by candidate mechanism, molecule type, target biology, development stage, and project objectives.<\/p>\n For EoE studies, evaluation may focus on eosinophil infiltration, inflammatory cell recruitment, tissue injury, epithelial barrier changes, and fibrosis-related alterations. For EgE and other EGIDs, the framework may be extended to additional gastrointestinal tissue sites and disease-related molecular signals.<\/p>\n 2. Multidimensional Efficacy Endpoint Evaluation<\/b><\/p>\n Efficacy assessment in eosinophilic gastrointestinal diseases cannot rely on a single endpoint. HKEY-ExE\u2122 1.0 combines histology, cytology, molecular biology, pathology, and biomarker analysis.<\/p>\n Depending on study objectives, endpoints may include:<\/p>\n 3. Type 2 and Eosinophilic Inflammation Biomarker Analysis<\/b><\/p>\n HKeyBio has established biomarker detection and analysis capabilities for key inflammatory pathways, including IL-4, IL-5, IL-13, TSLP, eotaxin family chemokines, and other molecules related to eosinophil recruitment, activation, and tissue infiltration.<\/p>\n These studies can help research teams evaluate expected pathway activity, inflammatory cascade modulation, and scientific rationale for later-stage development.<\/p>\n 4. Cross-Indication Translational Research Support<\/b><\/p>\n EoE, EgE, and other allergic inflammatory diseases share overlapping features, including type 2 inflammation, eosinophil recruitment, barrier dysfunction, and tissue remodeling. HKEY-ExE\u2122 1.0 supports mechanism validation, model selection, endpoint design, and translational pathway assessment for multi-indication strategies.<\/p>\n “EoE, EgE, and related EGIDs share important immuno-inflammatory characteristics, but they differ in affected tissue sites, pathological features, and endpoint evaluation requirements,” said a representative of HKeyBio. “HKEY-ExE\u2122 1.0 is designed to provide global drug developers with more systematic, interpretable, and mechanism-oriented preclinical research support.”<\/p>\n Looking ahead, HKeyBio will continue to strengthen disease model resources and translational research capabilities for EoE, EgE, and related EGIDs.<\/p>\n About HKeyBio<\/b><\/p>\n HKeyBio is a preclinical contract research organization focused on autoimmune and allergic diseases, providing in vivo pharmacology evaluation and translational research services from drug discovery through IND-enabling preparation. The company has established rodent and non-human primate preclinical platforms covering disease modeling, efficacy evaluation, mechanism-of-action studies, biomarker analysis, pathology testing, and translational medicine research.<\/p>\n HKeyBio’s core technical team has more than 20 years of autoimmune disease drug development experience and has supported more than 500 autoimmune disease-related IND research programs.<\/p>\n For more information, please contact:<\/b> <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-62817","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/62817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62817"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/62817\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
Website: www.hkeybio.com<\/a>
Email: tech@hkeybio.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"\n
Website: www.hkeybio.com<\/a>
Email: tech@hkeybio.com<\/a><\/p>\n